Sphera Funds Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-50,000
Closed -$3.71M 107
2023
Q3
$3.65M Hold
50,000
0.67% 51
2023
Q2
$4.16M Buy
+50,000
New +$4.18M 0.65% 55
2023
Q1
Sell
-70,000
Closed -$5.81M 98
2022
Q4
$5.81M Buy
+70,000
New +$5.67M 1.25% 28
2022
Q3
Sell
-437,748
Closed -$32.5M 90
2022
Q2
$32.5M Buy
+437,748
New +$32.9M 3.48% 8
2019
Q1
Sell
-45,000
Closed -$3.83M 123
2018
Q4
$3.23M Buy
+45,000
New +$3.63M 0.36% 60

Other funds holding XBI

Sphera Funds Management's XBI Position: Q4 2023 in Review

Sphera Funds Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2023, closing a stake of 50,000 shares — an estimated $3.71M sold.

Sphera Funds Management first reported a position in XBI in Q4 2018 and held it in 5 quarters. The position peaked at $32.5M in Q2 2022. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2023.

  • Sphera Funds Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2023 after selling out during the quarter.
  • Sphera Funds Management sold 50,000 State Street SPDR S&P Biotech ETF shares in Q4 2023, an estimated $3.71M.
  • Sphera Funds Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and held it in 5 quarters.
  • Sphera Funds Management's State Street SPDR S&P Biotech ETF position peaked at $32.5M in Q2 2022.
  • 745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2023.

Based on Sphera Funds Management's 13F filing for Q4 2023, filed 14 Feb 2024.